The CBS-inhibitory potency of 2,3,4-trihydroxybenzylhydrazine was similar to benserazide (IC50 of approximately 30 μM on recombinant human CBS) and—similar to benserazide and other CBS inhibitors—inhibited the proliferation of colon cancer cells in vitro without inducing detectable cytotoxicity, except at relatively high concentrations [329]. Here, CBS is linked to colonic neoplasm.